Abstract Body (Do not enter title and authors here): Introduction
The AngioStat initiative aimed to establish expert consensus on statin combination strategies involving ezetimibe and clopidogrel, focusing on their clinical relevance in optimizing lipid control and cardiovascular risk reduction.

Methods
The AngioStat consensus engaged 800 experts in dyslipidemia management, representing over 25,000 cumulative years of clinical experience. Participants evaluated 9 clinical statements related to statin combination therapy with ezetimibe and clopidogrel using a 5-point Likert scale. Data were analyzed using GraphPad v10.3.0, with strong consensus defined as a weighted score exceeding 100.

Results
The perception mapping revealed strong expert consensus on key lipid and antiplatelet strategies in cardiovascular care. Highest agreement was seen for clopidogrel plus statin in long-term post-PCI protection (score: 113.0) and TAVR patients on statin with SAPT (score: 111.9). Cumulative LDL-C exposure as a major atherosclerotic risk also scored high (score: 109.1). Other prioritized strategies included SAPT in high bleeding risk patients (score: 108.8), genetic lipid risk profiling (score: 107.7), and ezetimibe-based LDL-C lowering (score: 107.1). The overall mean response scores were: agree: 75±9.1 (95% CI 68 to 82), strongly agree: 32±12 (95% CI 22 to 41), p<0.0001

Conclusion
The AngioStat consensus confirms expert alignment on combining statins with ezetimibe and clopidogrel for optimized cardiovascular care, supporting their integration in long-term lipid and antiplatelet management strategies